Get 40% Off
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March.Read full update

EU regulator backs AstraZeneca and Daiichi's lung cancer drug (Sept. 15)

Published 18/09/2023, 11:26
© Reuters. AstraZeneca's cancer medicine Enhertu, a drug developed jointly with Japan's Daiichi Sankyo, is pictured in an undated handout image obtained by Reuters on June 27, 2022. AstraZeneca/Handout via REUTERS/File photo

(Corrects Sept. 15 story to say Enhertu showed objective response rate of 49%, not reduced tumour by 49%, in paragraph 2)

(Reuters) -AstraZeneca said on Friday its and Daiichi Sankyo's cancer drug Enhertu was recommended by the European Medicines Agency's human medicines committee as a monotherapy to treat patients with a type of non-small cell lung cancer (NSCLC).

The recommendation is based on the mid-stage data where Enhertu showed a confirmed objective response rate of 49% and a median duration of response of 16.8 months in patients previously treated for lung cancer.

The drug is already approved in the European Union as a treatment for patients with an advanced form of breast cancer.

Recommendations made by the human medicines committee will have to be formally approved by the European Commission.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.